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Summary
Activation of the basic-helix-loop-helix (bHLH) gene TAL1 (or SCL) is a frequent gain-of-function mutation in T cell acute
lymphoblastic leukemia (T-ALL). To provide genetic evidence that tal1/scl induces leukemia by interfering with E47 and
HEB, we expressed tal1/scl in an E2A or HEB heterozygous background. These mice exhibit disease acceleration and
perturbed thymocyte development due to repression of E47/HEB target genes. In tal1/scl thymocytes, we find the corepres-
sor mSin3A bound to the CD4 enhancer, whereas an E47/HEB/p300 complex is detected in wild-type thymocytes. Further-
more, tal1/scl tumors are sensitive to pharmacologic inhibition of HDAC and undergo apoptosis. These data demonstrate
that tal1/scl induces leukemia by repressing E47/HEB and suggest that HDAC inhibitors may prove efficacious in T-ALL
patients who express TAL1/SCL.
Introduction Tal1/scl/HEB heterodimers are readily detected (Hsu et al.,
1994a; O’Neil et al., 2001), and the related bHLH proteins LYL-1
T cell acute lymphoblastic leukemia (T-ALL) accounts for 10%– and BHLH-1 may contribute to leukemia by interfering with E
15% of pediatric and 25% of adult ALL cases (Ferrando et al., protein function(s). Consistent with this idea, a percentage of
2002). Activation of the basic-helix-loop-helix TAL1/SCL gene surviving E2A-deficient mice develop T cell leukemia/lymphoma
occurs by chromosomal translocation, interstitial deletion, or (Bain et al., 1997; Yan et al., 1997). Disruption of E2A function
mutation in over 60% of children and adults with T-ALL (Bash is also believed to be the consequence of chromosomal translo-
et al., 1995). In contrast to T-ALL induced by other oncogenes cations involving the LIM-only domain proteins, LMO1 and
such as HOX11 or MLL-ENL, patients with TAL1/SCL activation LMO2, recently also found to be activated in gene therapy-
respond poorly to therapy, with only 50% of patients surviving induced T-ALL (Kohn et al., 2003; O’Neil et al., 2001; Rabbitts,
5 years (Ferrando et al., 2002). 1998). Yet, how LMO1/2 inhibit E2A function and contribute to
TAL1/SCL heterodimerizes with class I or A bHLH proteins leukemia remains unclear. In some leukemic patients, LMO2
including E12, E47, HEB and E2-2 (Voronova and Lee, 1994; and TAL1/SCL are coexpressed (Ferrando et al., 2002), sug-
O’Neil et al., 2001; Hsu et al., 1991), and in hematopoietic cells gesting that leukemic transformation is dependent on the ex-
is part of a large transcriptional complex that includes GATA-1 pression of both the TAL1/SCL and LMO2 proteins. Consistent
and the LIM-only proteins LMO2 and Ldb-1 (Wadman et al., with this idea, a TAL1/SCL/LMO2/E2A complex is detected in
1997; Valge-Archer et al., 1994). Mice deficient for tal1/scl have a human T-ALL cell line (Ono et al., 1998), and leukemogenesis
no primitive or definitive hematopoiesis and exhibit angiogenic is observed in mice that express tal1/scl and LMO2 (Larson et
defects (Shivdasani et al., 1995; Visvader et al., 1998). Surpris- al., 1996). However, not all human T-ALL patients who express
ingly, conditional inactivation of tal1/scl in adult mice does not TAL1/SCL also express LMO1 or LMO2 (Ferrando et al., 2002).
result in hematopoietic defects, suggesting that tal1/scl is criti- Similarly, only one of six mouse tal1/scl tumors examined ex-
cal for the genesis of the hematopoietic stem cell (HSC), but presses LMO2 (J.S. and M.K., unpublished data), revealing that
not required for its maintenance (Mikkola et al., 2003). The func- LMO2 expression is also not required for tal1/scl-induced leuke-
tion of tal1/scl in the hematopoietic stem cell has suggested mogenesis in the mouse.
that tal1/scl activation in leukemia may stimulate the activation To test whether tal1/scl induces leukemia by interfering with
of genes important in stem cell expansion and/or self-renewal. E protein function(s), we expressed the tal1/scl oncogene in an
In mouse tal1/scl tumors and in Jurkat cells, a human leuke- E2A or HEB heterozygous background. We observe thymocyte
differentiation arrest and disease acceleration in tal1/scl/E2A/mic cell line that expresses TAL1/SCL, stable Tal1/scl/E47 and
S I G N I F I C A N C E
T-ALL patients who activate bHLH proteins like TAL1/SCL respond poorly to current therapies and are at high risk of treatment
failure. This study demonstrates that tal1/scl interferes with the transactivation of several E47/HEB target genes, critical for thymocyte
differentiation and survival. Repression is mediated by the recruitment of the mSin3A/HDAC1 corepressor complex to E47/HEB target
genes, raising the possibility that HDAC inhibitors may be beneficial in treating T-ALL patients with TAL1/SCL activation.
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and tal1/scl/HEB/ mice, providing genetic evidence that tal1/ mice exhibit thymocyte arrest at the DN2 stage of thymocyte
development with increases in the CD44-positive, CD25-posi-scl induces leukemia by interfering with E47/HEB. Consistent
tive DN thymocytes (Figure 1D). We found DN thymocyte devel-with the differentiation arrest, gene expression profiling of pre-
opment severely affected in tal1/scl/E2A/ and tal1/scl/HEB/malignant tal1/scl thymocytes reveals repression of several
mice, with evidence of arrest at the DN2 and DN3 stages, re-genes important for thymocyte differentiation. The expression
spectively. Tal1/scl expression in an E2A or HEB heterozygousof the E47/HEB target genes, Rag 2 and Pre-T, are decreased,
background perturbs thymocyte development and induces aon a per cell basis, in premalignant tal1/scl cells, and Rag 2 is
partial differentiation arrest similar to that observed in E2A- orfurther decreased in tal1/scl/E2A/ thymocytes. Tal1/scl medi-
HEB-deficient mice (Bain et al., 1997; Barndt et al., 1999).ates gene repression by depleting the E47/HEB heterodimer
and by recruiting the mSin3A/HDAC1 corepressor complex to
Disease acceleration in tal1/scl/E2A/target loci. The results of this study demonstrate that tal1/scl,
and tal1/scl/HEB/ micelike the leukemogenic fusion proteins PML-RAR and AML-1/
We have previously demonstrated that perturbation of thymo-ETO, contributes to leukemia by repressing gene expression
cyte development is a central feature associated with the devel-and inducing differentiation arrest.
opment of tal1/scl-induced leukemia in the mouse (O’Neil et al.,
2001, 2003). The thymocyte developmental defects observedResults
when tal1/scl is expressed in an E2A or HEB heterozygous
background suggested to us that leukemogenesis may be ac-Thymocyte development is perturbed in tal1/E2A/
celerated in these mice.and tal1/scl/HEB/ mice
Compared to tal1/scl transgenic mice on the wild-type back-Expression of tal1/scl in the thymus results in a 50% decrease
ground, tal1/scl/E2A/ and tal1/scl/HEB/ mice develop dis-in overall thymocyte cellularity (Figure 1A, p  0.0000003) and
ease rapidly within a median survival period of 216 days (p a 3- to 4-fold decrease in the absolute numbers of double
0.0001) and 143 days (p  0.0001), respectively (Figure 2). Inpositive thymocytes (p  0.002), as well as decreases in CD4
contrast, tal1/scl littermates on the mixed background, but wild-single positive thymocytes (p  0.00003) (Figure 1B). Increases
type with respect to E2A and HEB, develop disease at a similarin the absolute number of immature CD8 single positive thymo-
frequency as published tal1/scl transgenic mice on the FVB/Ncytes are also observed when tal1/scl is expressed in the wild-
background (Kelliher et al., 1996). Interestingly, tal1/scl/HEB/type background (not shown) (p 0.03). Analysis of thymocytes
mice develop disease more rapidly than tal1/scl/E2A/ micefrom tal1/E2A/ and tal1/HEB/ mice revealed severe de-
(p 0.0001). To provide additional evidence that an E2A or HEBcreases in the percentage of double positive thymocytes (aver-
haploinsufficiency collaborates with tal1/scl to induce leukemiaage 43% for tal1/scl/E2A/ and 40% for tal1/scl/HEB/) and
and does not reflect effects of the transgene insertion site, weincreases in the percentage of CD8 single positive thymocytes
mated an additional tal1/scl transgenic line with E2A/ mice.(Figure 1C), suggesting that tal1/scl expression in an E2A or
These tal1/scl/E2A/ mice exhibit similar perturbations in thy-HEB heterozygous background results in further decreases in
mocyte development (Supplemental Figure S1 at http://DP and CD4 single positive thymocytes. Although thymocyte
www.cancercell.org/cgi/content/full/5/6/587/DC1), and sixdevelopment is normal in E2A/ or HEB/ mice (Bain et al.,
mice developed leukemia with an average latency of 112 days.1997; Zhuang et al., 1996), tal1/scl expression in an E2A hetero-
Thus, disease acceleration reflects effects of tal1/scl on E2Azygous background results in a 3-fold decrease in the absolute
and HEB proteins and does not appear to reflect transgenenumber of DP thymocytes (Figure 1B; p  0.001) and 3-fold
insertion sites or genetic differences between the strains ofdecrease in CD4 SP thymocytes (p  0.02).
mice.The decrease in DP thymocytes and increase in CD8 SP
A highly significant increase in disease penetrance was also
thymocytes observed in tal1/scl mice may reflect an inability to
observed in both the tal1/scl/E2A/ and tal1/scl/HEB/ mice
express adequate amounts of the CD4 coreceptor (Figures 1B compared to tal1/scl transgenic mice. T cell lymphoblastic leu-
and 1C). The expression of the CD4 coreceptor, TCR  and  kemia is completely penetrant in tal1/scl/HEB/ mice and 80%
chains, and CD5 are decreased in mice deficient for E2A or penetrant in the tal1/scl/E2A/ background. In contrast, only
HEB, suggesting that these are bona fide E47/HEB target genes 28% of tal1/scl transgenic mice in the wild-type background
in thymocytes (Zhuang et al., 1996; Bain et al., 1997). Consistent develop disease in one year (Kelliher et al., 1996). Upon nec-
with the CD4 repression, we also observe 4- to 5-fold decreases ropsy, all animals exhibited lymphoblastic cells in the peripheral
in TCR  chain expression in thymocytes from tal1/scl/E2A/ blood and thymic masses, often accompanied by hepatospleno-
mice (not shown) as well as decreased CD5 expression (Table megaly and lymphadenopathy. Histopathological examination
2 and Figure 4), suggesting that tal1/scl interferes with the E47/ of the thymus revealed effacement of the normal thymic archi-
HEB heterodimer. tecture and the proliferation of lymphoblastic cells with promi-
Increases in the percentage of DN thymocyte precursors nent nucleoli and scant cytoplasm. The histological appearance
are observed in tal1/scl transgenic mice when compared to of the thymic tumors was indistinguishable from that previously
wild-type littermate controls (average 4% DN in wt versus 12% observed in tal1/scl transgenic mice (Kelliher et al., 1996). In
DN in tal1/scl; p  .00008). The percentage of DN thymocyte addition, examination of other tissues revealed evidence of tu-
precursors is further increased in tal1/scl/E2A/ and tal1/scl/ mor infiltration to organs such as liver and kidney.
HEB/ mice (16.6% DN in tal1/scl/E2A/ and 23% DN in tal1/
scl/HEB/ mice), suggesting that DN thymocyte development Tumors induced are clonal or oligoclonal and display
may be more severely affected in these mice than when tal1/ a variety of immunophenotypes
scl is expressed on a wild-type background (p  .027 for tal1/ The disease acceleration observed when tal1/scl is expressed
in an E2A or HEB heterozygous background suggested to usscl/E2A/; p  .025 for tal1/scl/HEB/). Tal1/scl transgenic
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Figure 1. Thymocyte development is severely perturbed when Tal1/scl is expressed on an E2A/ or HEB/ background
A: Decreased thymocyte cellularity in tal1/scl transgenic mice. Total thymocyte numbers from four-week-old, wild-type (wt), tal1/scl, tal1/scl/E2A/, and
tal1/scl/HEB/ mice. Tal1/scl reduces thymocyte cellularity when expressed on a wt background (p  .0000003). Tal1/scl expression on the E2A/ or HEB/
background does not cause further reductions in cellularity that are statistically significant.
B: Tal1/scl expression is associated with reductions in the absolute numbers of DP and CD4 SP thymocytes. The absolute numbers of DP and CD4 SP
thymocytes in wt, tal1/scl, tal1/scl/E2A/, and tal1/scl/HEB/ in preleukemic, four-week-old mice are represented. Compared to littermate controls, Tal1/
scl expression results in a reduction in the absolute numbers of DP thymocytes (p  .002) and CD4 SP thymocytes (p  .00003). Tal1/scl expression on the
E2A/ background results in further decreases in the absolute numbers of DP thymocytes (p  .001) and CD4 SP thymocytes (p  .02).
C: DP thymocyte development is further perturbed when Tal1/scl is expressed on an E2A/ or HEB/ background. Thymocytes from four-week-old wt,
tal1/scl, tal1/scl/E2A/, and tal1/scl/HEB/ mice were stained with CD4-Cy and CD8-FITC and analyzed by flow cytometry.
D: The percentage of DN thymocyte precursors is increased when Tal1/scl is expressed on an E2A/ or HEB/ background. Thymocytes from 4-week-old
wt, tal1/scl, tal1/scl/E2A/, and tal1/scl/HEB/ mice were stained with antibodies for the lineage markers IgM, Ter119, Gr1, Mac1, PanNK, CD3, CD4, and
CD8 as well as CD25-PE and CD44-FITC. A representative profile of the lineage negative cells stained with CD25-PE and CD44-FITC is shown. Tal1/scl
increases the percentage of DN thymocytes compared to littermate controls (p  .00008). Tal1/scl expression on an E2A/ or HEB/ background further
increases the percentage of DN precursors (p  0.03 for tal1/scl/E2A/ and p  0.03 for tal1/scl/HEB/).
that polyclonal tumors may develop in these mice. To examine the tumor target cell. All tumors were of T cell origin but appear
to be at various stages of thymocyte development (Table 1).this possibility, DNA isolated from tal1/scl/E2A/ and tal1/scl/
HEB/ tumors was digested with HindIII and analyzed by Diverse tumor phenotypes were also observed in tal1/scl trans-
genic mice (Kelliher et al., 1996). However, about twenty percentSouthern blot analysis with a TCR J2 probe (Figure 3A). All
tumors analyzed were clonal or oligoclonal, and in most cases, of the tal1/scl/E2A/ and tal1/scl/HEB/ tumors failed to ex-
press CD3, CD4, and CD8, indicating that a more immature cellboth TCR  alleles were rearranged. Similar to what is observed
in E2A-deficient mice (Bain et al., 1997), clonal or oligoclonal type may be transformed in some of the tal1/scl/E2A/ or
HEB/ mice.tumors were observed in tal1/scl/E2A/ or HEB/mice, reveal-
ing that a deficiency of E2A and HEB proteins is not sufficient
to induce leukemia in these mice and that additional genetic Disease acceleration is not accompanied by loss
changes are required. of heterozygosity in tal1/scl/E2A/ mice
Tumors from tal1/scl/E2A/ and tal1/scl/HEB/ mice were The observation that a percentage of E2A-deficient mice are
susceptible to the development of T cell leukemia/lymphomaalso analyzed by flow cytometry to determine the phenotype of
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Figure 2. Accelerated leukemogenesis when tal1/scl is expressed in an E2A
or HEB heterozygous background
Kaplan-Meier survival plot of tal1/scl, tal1/scl/E2A/, and tal1/scl/HEB/
mice. The cohort of tal1/scl mice consisted of n  75 animals, the tal1/scl/
E2A/ cohort consisted of n  102 animals, and the tal1/scl/HEB/ cohort
consisted of n  114 animals. Tarone-Ware statistical analysis confirmed a
highly statistically significant difference in survival when tal1/scl transgenic
mice in the wild-type background are compared to tal1/scl in the E2A/ Figure 3. Tal1/scl/E2A/and tal1/scl/HEB/ tumors are clonal or oligoclonal
(p  0.0001) or HEB/ (p  0.0001) genetic backgrounds. The difference and do not exhibit loss of heterozygosity
in survival between tal1/scl/HEB/ mice and tal1/scl/E2A/ mice was also
A: Tumors isolated from tal1/scl/E2A/ or HEB/ mice are clonal or oligoclo-
statistically significant (p  0.0001). All animals were monitored daily for
nal. DNA prepared from tumors and wild-type genomic tail DNA was di-
signs of disease. Upon onset of disease, the mice were sacrificed and a
gested with HindIII and analyzed by Southern blot analysis. T cell receptor
postmortem examination was performed.
J chain rearrangements were detected with a probe that identified a 5
kb DNA fragment in the germline position of genomic tail DNA (lane T).
B: Disease acceleration is not accompanied by loss of heterozygosity in
tal1/scl/E2A/ mice. E2A/ and E2A/ tail DNA, tal1/scl/E2A/ tail DNA,
and DNA prepared from tumors from the same tal1/scl/E2A/ mice wasled to the idea that the E2A locus may act as a lymphoid-specific
digested with BamHI and analyzed by Southern blot analysis. Using a portiontumor suppressor (Bain et al., 1997; Yan et al., 1997). Hence,
of an E2A genomic clone as a probe, the wild-type E2A allele was identified
tumors that develop in tal1/scl/E2A/ mice may exhibit loss of as a 13 kb fragment and the mutant allele as a 10 kb fragment.
heterozygosity (LOH). To examine this possibility, we isolated
DNA from tumors derived from tal1/scl/E2A/ mice and ana-
lyzed the E2A locus by Southern blotting (Figure 3B). All tal1/
scl/E2A/ tumors tested retained the wild-type allele of E2A, the tal1/scl transgenic mice (O’Neil et al., 2003), we found the
indicating that LOH is not a feature associated with disease lymphoid-specific cyclin D3 decreased in thymocytes that ex-
acceleration in tal1/scl/E2A/ mice. However, loss of E2A ex- pressed Tal1/scl (Table 2). Moreover, the expression of several
pression in the tal1/scl/E2A/ tumors could involve methylation genes important in thymocyte differentiation was also reduced
of regulatory sequences. To confirm that the remaining E2A in tal1/scl thymocytes, including those encoding CD3, CD6,
allele is expressed, we prepared nuclear lysates from tal1/scl/ CD5, RAG1, RAG2, and ROR (Figure 4 and data not shown).
E2A/ tumors and were able to detect E47 expression by immu- Some of the genes repressed in tal1/scl thymocytes have been
noblotting (not shown). Similar results were obtained on tumors previously thought to be regulated by E47/HEB heterodimer,
from tal1/scl/HEB/ mice, indicating that tal1/scl is not simply notably RAG1/2 and CD5 (Bain et al., 1994; Schlissel et al.,
cooperating with loss of E2A or HEB proteins to induce leukemia 1991; Zhuang et al., 1996). Other genes such as the retinoid-
in mice. related orphan receptor  (ROR) have been shown to be impor-
tant in thymocyte development (He, 2002; Littman et al., 1999;
Thymic expression of the tal1/scl oncogene Sun et al., 2000), but have not been linked to E47/HEB regula-
is associated with gene repression tion. Interestingly, ROR-deficient mice exhibit decreases in
To identify potential target genes deregulated by tal1/scl activa- double positive and CD4 single positive thymocytes and de-
tion, we performed gene expression profiling of premalignant velop T cell leukemia/lymphoma at high incidence (Sun et al.,
tal1/scl thymocytes using high-density DNA microarrays. We 2000; Ueda et al., 2002). To confirm whether ROR expression
isolated RNA from sorted CD4- and CD8-positive premalignant is decreased in premalignant tal1/scl thymocytes, we prepared
thymocytes and used it to interrogate Affymetrix DNA microar- total cell lysates from thymocytes from tal1/scl transgenic and
rays, representing 6,000 known genes and 6,000 EST clusters. control littermates. We found ROR levels decreased in cells
Transcription profiles of sorted double positive thymocytes from that express tal1/scl compared to thymocytes from control lit-
age-matched, wild-type and tal1/scl transgenic mice were com- termates (Figure 4C). Moreover, repression of ROR expression
was maintained in all seven of the tal1/scl tumors examined,pared. Consistent with the differentiation arrest observed in
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Table 1. Immunophenotypes of tal1/E2A/ and tal1/HEB/ tumors
Animal number Genotype CD3 CD4 CD8 CD4, CD8 Phenotype Survival (days)
737 tal1/E2A/ 4 12 4 8 DP 74
6778 tal1/E2A/ 2 0 43 0 ISPCD8 85
6831 tal1/E2A/ 32 0 97 2 CD8 104
8583 tal1/E2A/ 32 1 71 0 CD8 89
388 tal1 E2A/ 1 0 0 0 DN 92
9845 tal1/E2A/ 31 90 93 78 DP 144
135 tal1/HEB/ 45 17 98 18 DP 105
138 tal1/HEB/ 69 8 97 8 CD8 100
8959 tal1/HEB/ 4 29 93 30 DP 116
9193 tal1/HEB/ 5 19 46 18 DP 81
9205 tal1/HEB/ 26 70 92 70 DP 70
9232 tal1/HEB/ 8 74 98 75 DP 83
8906 tal1/HEB/ 93 1 6 0 DN 67
Tumors were stained with antibodies to CD3, CD4, and CD8 and analyzed by flow cytometry. Tumors were considered positive if 10% of the tumor stained
positive for the antibody.
suggesting that ROR repression may be important in leukemo- 448 for tal1/scl), indicating reduced Rag 2 expression in tal1/
scl double positive thymocytes. Reduced Rag 2 expression wasgenesis. Although not previously implicated as an E47/HEB
target gene, conserved, tandem E box sequences are present also observed in the DN thymocyte precursor populations upon
tal1/scl expression (not shown). If tal1/scl functions by inhibitingin the regulatory region of the mouse and human ROR genes,
suggesting that ROR may also be regulated by the E47/HEB E47/HEB-mediated transcription of Rag 2, then one might pre-
dict further decreases in Rag 2 expression in tal1/scl/E2A/ orheterodimer.
tal1/scl/HEB/preleukemic thymocytes. To test this possibility,
The E47/HEB target genes rag 2 and pre-T we mated our tal1/scl/E2A/ mice to the Rag 2-GFP mice. In
are reduced on a per cell basis in tal1/scl all mice examined, we found Rag 2-driven expression of GFP
and tal1/scl/E2A/ thymocytes further reduced in thymocytes from tal1/scl/E2A/ mice (MFI
Our microarray experiment suggests that tal1/scl expression 278) compared to tal1/scl transgenic mice (MFI  448), indicat-
affects the expression of Rag1/Rag2 recombinases, required ing further E47/HEB inhibition in tal1/scl/E2A/ mice. Com-
for T and B cell development (Shinkai et al., 1992). To validate pared to wild-type mice, tal1/scl expression results in an aver-
these findings and to test whether Rag 2 expression is affected age 2.73-fold decrease in Rag 2-driven GFP expression,
by tal1/scl expression, we mated our tal1/scl transgenic mice whereas tal1/scl expression on an E2A/ background results
to transgenic mice that carry a BAC in which GFP has been in an average 4.38-fold decrease in Rag 2 expression that is
introduced into the mouse Rag 2 locus by homologous recombi- statistically significant (p  0.0003).
nation (Yu et al., 1999). Thymocytes from age-matched, prema- In addition to the recombinase genes Rag 1/2, the E47/HEB
lignant tal1/scl mice were stained with antibodies against CD4 heterodimer has also been implicated in regulation of the pre-
and CD8, and the GFP levels in the various thymic subpopula- T chain of the pre T receptor, required for DN thymocyte expan-
tions were examined. The mean fluorescence intensity (MFI) of sion and survival (Herblot et al., 2000; Petersson et al., 2002;
the Rag 2-driven GFP was consistently reduced on a per cell Takeuchi et al., 2001; Tremblay et al., 2003). To determine
basis in tal1/scl double positive thymocytes compared to control whether tal1/scl affects the expression of pre-T, we used a
littermates (Figure 5A; MFI  1087 for wt, compared to MFI  similar strategy and mated our tal1/scl transgenic mice to mice
in which the expression of GFP is under the control of the pre-
T promoter (Reizis and Leder, 2001). We observe a 2- to 3-fold
decrease in the pre-T-driven GFP expression in tal1/scl DN3
Table 2. Genes activated or repressed by Tal1/scl thymocytes (Figure 5B; MFI  747 for wt compared to MFI 
Description of the gene (accession number) Fold change 323 for tal1/scl). Pre-T expression was also reduced in the
tal1/scl E2A/ animals examined (Figure 5B; MFI  184), butGM2 activator protein (U09816) 7.3
Homeobox protein Pknox1 (AF061270) 4.7 not significantly reduced when compared to tal1/scl in the wild-
CD3 antigen (M23376) 3 type background. The reduced transcription of Rag 2 and Pre-
Recombination activating gene 1 (M29475) 3.9 T in nearly all tal1/scl thymocytes (Figure 5) suggests that the
Cyclin 3 (M86183) 4.2
thymocyte developmental abnormalities observed upon tal1/Dishevelled 2, dsh homolog (U24160) 5.1
scl activation may be mediated by reduced Rag 2 and Pre-TRAR-related orphan receptor  (AF019660) 5.6
Cdc2/CDC-28-like protein kinase 3 (AF033565) 6.8 expression.
Recombination activating gene 2 (M64796) 6.9
Interleukin 4 receptor (M27960) 8.1
Tal1/scl recruits the corepressor mSin3AZinc finger protein (U14556) 9.2
to the CD4 enhancerHOX-4.4 and HOX-4.5 (X62669) 10.6
G-protein-coupled receptor 6-B (Y15798) 14.7 Our previous work demonstrated the presence of stable Tal1/
CD6 antigen (U12434) 16 scl/E47 and Tal1/scl/HEB heterodimers in preleukemic thymo-
CD5 antigen (M15177) 17.5 cytes and tumors isolated from tal1/scl transgenic mice (O’Neil
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Figure 4. Gene repression in preleukemic tal1/scl
thymocytes
A: CD5 expression is reduced in tal1/scl thymo-
cytes. Thymocytes from four-week-old wild-type
and tal1/scl transgenic mice were stained with
anti-CD5 Cy and analyzed by flow cytometry.
B: CD3 expression is reduced in tal1/scl thymo-
cytes. Thymocytes from four-week-old wild-type
and tal1/scl transgenic mice were stained with
anti-CD3 PE antibodies and analyzed by flow cy-
tometry. A representative profile is shown.
C: CD6 expression is decreased in preleukemic
tal1/scl thymocytes and in tal1/scl tumors. Total
RNA was isolated from wild-type, tal1/scl preleu-
kemic thymocytes and from tal1/scl tumors. The
RNA was separated on a 1% agarose gel and
transferred to a membrane that was probed with
the mouse CD6 cDNA. To insure equal loading,
RNA was stained with ethidium bromide.
D: ROR expression is decreased in preleukemic
tal1/scl thymocytes and tumors. Twenty-five mi-
crograms of protein from wild-type, preleukemic
tal1/scl thymocytes and tal1/scl tumors was sep-
arated on a 10% SDS-PAGE gel and transferred to
a membrane. The membrane was then probed
with anti-ROR. The blot was then stripped and
reprobed with an antibody against  actin to
control for protein loading.
et al., 2001). Thus, tal1/scl may repress E47/HEB target genes does not function like an Id protein and inhibit E47/HEB-medi-
ated transcription by sequestering E47 into non-DNA bindingby depleting E47/HEB heterodimers or by modifying E47/HEB
transcriptional activity. complexes.
Previous work has demonstrated that the Tal1/scl proteinTo determine whether the Tal1/scl/E47 or HEB heterodimers
are localized to regions of gene repression, we used chromatin associates with mSin3A in undifferentiated MEL cells (Huang
and Brandt, 2000). Thus, we hypothesized that Tal1/scl mayimmunoprecipitation to ask whether E47/HEB or Tal1/scl/E47
heterodimers bound the regulatory regions of the CD4 gene. cause gene repression in leukemia by displacing coactivators
with corepressor complexes. To test this possibility, we per-Thymocytes from age-matched, preleukemic tal1/scl and wild-
type mice were treated with formaldehyde and extracts were formed additional chromatin immunoprecipitation experiments
using antibodies for the coactivator p300 and the corepressorimmunoprecipitated using antibodies against Tal1/scl or E2A,
or with an irrelevant isotype-matched control antibody (anti- mSin3A. In wild-type thymocytes, the 200 bp band is amplified
from DNA immunoprecipitated with an anti-p300 antibody, indi-Rip1). PCR was performed on the immunoprecipitated DNA
using primers that flank the tandem E box consensus sequences cating that the coactivator p300 is also bound to the CD4 en-
hancer sequence. E proteins have been shown to interact withof the mouse CD4 enhancer (Sawada and Littman, 1993). A 200
bp fragment was amplified from DNA immunoprecipitated with histone acetyltransferases and the transcriptional coactivators
p300, CBP, and PCAF (Bradney et al., 2002; Eckner et al., 1996).an anti-E2A antibody from wild-type thymocytes. The 200 bp
fragment was also detected when tal1/scl thymocyte DNA was Consistent with the CD4 repression observed in the preleukemic
tal1/scl thymocytes (Figure 1), the coactivator p300 is not de-immunoprecipitated with an anti-Tal1/scl or anti-E2A antibod-
ies, indicating that the Tal1/scl/E47 heterodimer occupies the tected at the CD4 locus when tal1/scl thymocytes are immuno-
precipitated. Rather, the corepressor mSin3A is readily detectedCD4 enhancer (Figure 6A). These studies reveal that Tal1/scl
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Figure 5. Rag2 and pre-T expression is reduced
in tal1/scl and tal1/scl/E2A/ mice
A: Rag2 expression is decreased on a per cell
basis in tal1/scl and tal1/scl/E2A/ thymocytes.
Thymocytes from four-week-old, rag2-GFP, tal1/
scl/rag2-GFP, and tal1/scl/E2A//rag2-GFP mice
were stained with anti-CD4 PE and anti-CD8 Cy
and analyzed by flow cytometry. The mean fluo-
rescent intensity of the GFP was determined for
the double positive (A) and double negative thy-
mocyte populations (not shown). In the DP thy-
mocyte population, tal1/scl expression in an
E2A/ background results in a statistically sig-
nificant decrease in rag2-GFP expression when
compared to tal1/scl in the wt background (p
.0003).
B: Pre-T expression is also reduced in tal1/scl
DN3 thymocytes. Thymocytes from four-week-
old, preT-GFP, tal1/scl/preT-GFP, and tal1/scl/
E2A//preT-GFP mice were stained with anti-
bodies for the lineage markers IgM, Ter119, Gr1,
Mac1, PanNK, CD3, CD4, and CD8 as well as
CD25-PE and CD44-FITC. The mean fluorescent
intensity of GFP was determined for the DN3 pop-
ulations.
bound to the CD4 enhancer (Figure 6B). In contrast, the GAPDH fects on E47/HEB transcriptional activity. Consistent with its
function as a lymphoid-specific tumor suppressor, ectopic E47locus was amplified from wt and tal1/scl input DNA, but not
from the immunoprecipitated extracts (Figure 6B). These results expression in T cell tumors that arise in E2A/ mice results in
apoptosis (Engel and Murre, 1999), suggesting that in additionsuggest that tal1/scl represses CD4 transcription by binding to
the E box sequences in the CD4 enhancer and bringing in the to its roles in differentiation, the E47/HEB heterodimer also has
proapoptotic activities.corepressor mSin3A. Consistent with its association with the
mSin3A corepressor complex (Zhang et al., 1997), the histone
deacetylase HDAC1 is detected at the CD4 enhancer when tal1/ Discussion
scl preleukemic thymocytes, but not wild-type thymocytes, are
immunoprecipitated (not shown). Although frequently activated in human T-ALL patients, the
mechanism(s) by which Tal1/scl contributes to leukemia/lym-The recruitment of mSin3A/HDAC1 complex to the CD4
locus and potentially other E47/HEB target genes suggested to phoma remains unclear. Studies suggest that Tal1/scl may
transactivate the expression of novel target genes in leukemiaus that mouse tal1/scl tumors may be sensitive to HDAC inhibi-
tors. Treatment with the HDAC inhibitor TSA induced apoptosis (Cohen-Kaminsky et al., 1998; Hsu et al., 1994b) and that the
LIM-only protein LMO2 is required for tal1/scl-induced leukemo-in all six mouse tal1/scl tumors tested, resulting in the death of
75% to 95% of the treated tumor cells, whereas thymocytes genesis (Larson et al., 1996). We demonstrate that tal1/scl trans-
forms mouse T cells in the absence of LMO2 activation bywere only moderately sensitive to TSA treatment (25% death
due to TSA treatment) (Figure 6C). To test the specificity of the inducing differentiation arrest and by interfering with E47/HEB
function(s). Both tal1/scl/E2A/ and tal1/scl/HEB/ mice de-TSA response, we also treated tumor cell lines that do not
express TAL1/SCL for their TSA sensitivity. In contrast to the velop disease rapidly and with increased penetrance. Disease
acceleration is accompanied by induction of a more severetal1/scl tumors, the TAL1/SCL–negative tumors, Molt 13 and
PEER, appear resistant to TSA treatment (Figure 6C). thymocyte developmental arrest in tal1/scl/E2A/ and tal1/scl/
HEB/ mice compared to transgenic mice expressing Tal1/sclTSA treatment of tal1/scl tumors induced apoptosis, as
treated tumors stained positive for Annexin V/PI and exhibited or a DNA binding mutant of Tal1/scl (O’Neil et al., 2001, 2003).
Thus, this work also reveals that differentiation arrest is centralcaspase 3 activation (Supplemental Figure S2 at http://
www.cancercell.org/cgi/content/full/5/6/587/DC1). HDAC inhi- for disease development and suggests that E2A proteins may
directly regulate cell cycle in thymocyte precursors.bition may stimulate tal1/scl tumor cell apoptosis via direct ef-
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Tal1/scl is expressed in an E2A or HEB heterozygous back-
ground. Consistent with these studies, our gene expression
profiling reveals evidence of gene repression during the preleu-
kemic phase of the disease.
E47/HEB heterodimers appear to regulate CD4 expression
in part by recruiting the coactivator p300 to the enhancer. In
contrast, CD4 expression is reduced in preleukemic tal1/scl
thymocytes and further reduced in tal1/scl/E2A/ or HEB/
thymocytes, supporting the idea that E47/HEB activity is dimin-
ished in these mice. In addition to depleting the E47/HEB hetero-
dimer, tal1/scl represses E47/HEB target gene expression by
recruiting the mSin3A/HDAC1 corepressor to target loci. This
observation provides a new mechanism to explain how tal1/scl
contributes to leukemogenesis. Rather than operating like an
Id and inhibiting the ability of E proteins to bind DNA, tal1/scl
directly represses gene transcription by recruiting corepressor
complexes to the E47/HEB target gene, CD4. It seems likely
that decreased expression of the other E47/HEB target genes,
including TCR  and , CD5, rag 2, and pre-T, may also be
mSin3A/HDAC1-mediated. The fact that all the mouse tal1/scl
tumors examined were highly sensitive to HDAC inhibitors raises
the possibility that T-ALL patients with TAL1/SCL activation
may also be responsive to HDAC inhibitors. This is an important
finding, as many of these patients fail on modern combination
chemotherapy and specific therapies are urgently needed (Fer-
rando et al., 2002). Finally, tal1/scl repressive effects may not
be limited to E47/HEB target genes that regulate thymocyte
differentiation, but may include other genes that regulate prolif-
eration and survival.
A critical remaining question is how thymocyte differentia-
tion arrest induced by tal1/scl expression predisposes thymo-
cytes to leukemia. One possibility may be that additional muta-
tions are incurred during the DN arrest, where the thymocyte
Figure 6. Tal1/scl recruits the corepressor mSin3A to the CD4 locus and tal1/ precursor undergoes extensive cell divisions. Consistent with
scl tumors are sensitive to the HDAC inhibitor, TSA
this idea, increased cell cycling is observed in E2A-deficient
A: Tal1/scl/E2A complexes bind the mouse CD4 enhancer. Chromatin immu-
DN3 precursors, suggesting that E2A proteins function as cellnoprecipitation assays were performed on thymocytes from four-week-old
cycle inhibitors in thymic precursors (Engel and Murre, 2004).wild-type and preleukemic tal1/scl mice using antibodies to E2A and Tal1/
scl. No antibody and immunoprecipitations with an irrelevant, anti-Rip1 In addition to aberrant cell cycling, survival pathways may also
(receptor interacting protein 1) were used as negative controls. Input- be activated during the differentiation arrest and maintained
sheared DNA served as a positive control. Thirty cycles of PCR amplification throughout leukemic progression. The antiapoptotic transcrip-were performed on the immunoprecipitated DNA with primers specific for
tion factor NF-	B is activated in tal1/scl thymocytes, and NF-the mouse CD4 enhancer region.
B: The corepressor msin3A is recruited to the CD4 enhancer in tal1/scl thymo- 	B activity is maintained in mouse tal1/scl tumors, and observed
cytes. Chromatin immunoprecipitation was performed with antibodies to in a majority of human T-ALL samples (O’Neil et al., 2003; Kim
the corepressor mSin3A or coactivator p300 or with negative control anti- et al., 2002; Kordes et al., 2000). Identification of the antiapo-bodies. A control PCR reaction was performed on the chromatin immuno-
ptotic NF-	B target genes in tal1/scl leukemic cells will be theprecipitated extracts and inputs using primers to mouse GAPDH.
C: Tal1/scl tumors are sensitive to HDAC inhibition. Six tal1/scl tumor cells focus of future work.
were left untreated or treated with TSA for 24 hours and tumor cell viability
determined by trypan blue exclusion or by the percentage of apoptotic Experimental procedures
cells determined by staining with Annexin V/PI (Supplemental Data at http://
www.cancercell.org/cgi/content/full/5/6/587/DC1). Thymocytes and hu- Mice and tumor cell culture
man tumor cell lines that do not express TAL1/SCL (Molt-13, PEER) were also
Proximal lck-tal1/scl transgenic mice have been described previously (Kel-
treated with TSA and cell viability determined.
liher et al., 1996). E2A heterozygous mice and HEB heterozygous mice were
generously provided by Dr. Cornelius Murre (UCSD) and Dr. Yuan Zhuang
(Duke), respectively. B6 E2A and HEB heterozygous mice were backcrossed
with FVB/N mice for three generations before being mated to tal1/scl trans-We found that expression of the E47/HEB target genes CD4,
genic mice for disease study. Disease development was monitored in tal1/TCR, and CD5 decreased in tal1/scl DP thymocytes and rag
scl/E2A/ and tal1/scl/HEB/ mice and compared to littermate controls.
2 and pre-T decreased in tal1/scl DN thymic precursors. The Rag2-GFP mice were provided by Dr. Michel Nussenzweig (Rockefeller Uni-
expression of rag 2 and pre-T are further reduced in tal1/ versity), and pre-T-GFP mice were provided by Drs. Boris Reizis and Philip
scl/E2A/ or tal1/scl/HEB/ mice, suggesting that decreased Leder (Harvard Medical School). Tal1/scl tumor cell lines were plated at 1 

expression of these genes may be responsible for the severe 106 cells/ml and left untreated or treated with trichostatin A (Sigma) at a
concentration of 90 nM. Cell viability was assessed 24 hr after treatment bydifferentiation arrest and disease acceleration observed when
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either trypan blue staining or by staining with Annexin V/PI followed by flow reactions were separated by electrophoresis on a 6% acrylamide gel. The
gel was then dried and exposed to film.cytometry.
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